Curadev Immunology

Get in Touch

Your Heading

Transforming Treatment for IPF and Liver Fibrosis

We are dedicated to pioneering next-generation selective TNIK inhibitors aimed at disrupting organ fibrosis. Our innovative solutions promise to unlock new treatment modalities for patients suffering from idiopathic pulmonary fibrosis (IPF) and liver fibrosis.

CRD06

Curadev Immunology has nominated COMPOUND 6, its lead small-molecule TNIK inhibitor as a IND candidate. The TNIK inhibitor program has yielded potent and selective TNIK inhibitors that alleviate bleomycin induced pulmonary fibrosis and high fat diet induce liver fibrosis in murine models.